Gene Therapy Media Market Size, Share, Trends, & Industry Analysis Report
By Product (Specialty Media, Serum-free Media, Classical Media, Other Products), By Vector Type, By End User, and By Region – Market Forecast, 2025–2034
- Published Date:Oct-2025
- Pages: 126
- Format: PDF
- Report ID: PM6504
- Base Year: 2024
- Historical Data: 2020-2023
Overview
The gene therapy media market was valued at USD 408.06 million in 2024 growing at a CAGR of 17.27% from 2025-2032. Rising demand for gene therapy products in rare and chronic diseases is driving growth in cell and gene therapy manufacturing facilities worldwide.
Key Insights
- Specialty media segment led in 2024 due to widespread use in viral and non-viral vector production.
- Serum-free media segment is expected to grow fastest, driven by demand for scalable and animal-component-free formulations.
- North America dominated in 2024 with advanced gene therapy manufacturing infrastructure.
- The U.S. led the region due to high R&D investment and regulatory support for gene therapies.
- Asia Pacific is projected to grow fastest with expanding gene therapy facilities and rising awareness of targeted treatments.
- China led APAC due to government initiatives and growing investments in biotechnology manufacturing.
Industry Dynamics
- Rising demand for gene therapy for rare and chronic diseases is driving adoption of specialized gene therapy media.
- Growth of cell and gene therapy manufacturing facilities worldwide is increasing the use of advanced culture media solutions.
- High cost of specialized media and stringent quality requirements remain key market challenges.
- Advancements in serum-free formulations, AI-enabled bioprocessing, and tailor-made media are opening up new growth avenues.
Market Statistics
- 2024 Market Size: USD 408.06 Million
- 2034 Projected Market Size: USD 477.04 Million
- CAGR (2025-2034): 17.27%
- North America: Largest Market Share
Gene therapy media are dedicated culture solutions for the proliferation, transfection, and production of viral and non-viral vectors employed in gene therapies. These media are essential for maximizing cell health, vector titer, and overall process efficacy, and are increasingly becoming part of AI-enabled bioprocessing and automated manufacturing platforms.
Growing demand for gene therapy for genetic and chronic disorders, and increasing construction of cell and gene therapy production facilities globally, is fueling the growth of advanced gene therapy media adoption. Biotechnology firms and research centers are increasingly turning to these media to increase vector manufacturing, reproducibility, and therapeutic efficiency.
Key companies are creating serum-free, tailor-made, and high-performance media formulations to address changing process needs. Increasing clinical trials, collaboration between media manufacturers and gene therapy manufacturers, and expansion in emerging markets are providing new reasons for market growth. In October 2025, Lonza extended its TheraPEAK gene therapy media with 293-GT Medium for production of AAV and AmpliCell Cytokines for sustaining immune cell growth, increasing scalable gene therapy manufacturing.
Drivers & Opportunity
Increasing demand for gene therapy products in rare and chronic diseases: Increasing incidence of rare and long-term conditions is increasing demand for gene therapies targeted at specific genes. Approximately 25–30 million Americans, or nearly 10% of the US population, suffer from rare diseases that individually affect fewer than 200,000 individuals, National Organization for Rare Disorders (NORD) estimates. This is creating demand for specialized gene therapy media to facilitate better vector production and treatment yields. Media makers are creating products that promote cell growth, transfection, and consistency of process.
Growth of cell and gene therapy manufacturing facilities worldwide: Expansion of gene therapy production facilities is driving the demand for high-quality culture media. Scalable, high-performance media solutions are required for complex vectors and cell types. Biotech firms are embracing optimized, serum-free, and tailored media to facilitate large-scale production economically.
Segmental Insights
Product Analysis
Based on product, the segmentation includes specialty media, serum-free media, classical media, and other products. The specialty media segment led the market in 2024 due to immense adoption in the manufacture of viral and non-viral vectors. Additionally, steady performance in large-scale gene therapy production is backing sustained preference across biotech and pharma companies globally.
The serum-free media segment projected to record the highest CAGR over the forecast period based on increasing demand for formulations free from animal components. In addition, adoption in scalable and reproducible gene therapy processes is fueling rapid market expansion globally.
Vector Type Analysis
Based on vector type, the segmentation includes AAV production, LV production, and other vectors. The AAV production segment dominated the market in 2024, driven by widespread application in rare and chronic genetic disorder therapies. Additionally, strong clinical adoption and stable vector performance are driving its continued market leadership. In September 2025, Fujifilm Biosciences introduced BalanCD HEK293 Perfusion A, a gene therapy medium that maximizes AAV production by enabling high-density HEK293 cell culture.
The segment of LV production stands to grow at the highest CAGR over the forecast period as a result of increasing application in CAR-T therapy and personalized medicine. In addition, technological advancements in vector manufacturing are enhancing efficiency and scalability.
End User Analysis
Based on end user, the segmentation includes pharmaceutical and biotechnology companies, contract development & manufacturing organizations (CDMOs) & CROs, and research and academic institutes. Pharmaceutical and biotechnology companies dominated the market in 2024 due to large-scale gene therapy manufacturing and high R&D investments. Moreover, strategic collaborations with media suppliers are supporting consistent adoption of advanced culture solutions.
CDMOs and CROs are expected to grow at the fastest CAGR during the forecast period due to rising outsourcing of gene therapy production. In addition, adoption of standardized and scalable media solutions is enhancing process efficiency and output quality.
Regional Analysis
North America led the gene therapy media market due to a high concentration of gene therapy R&D and large-scale biopharmaceutical manufacturing facilities. Additionally, advanced regulatory systems facilitating gene therapy approvals are boosting market uptake. Furthermore, robust partnerships between research centers and biotech firms are fueling growth.
The U.S. Gene Therapy Media Market Insights
The U.S. dominated the gene therapy media industry owing to increasing investment in gene therapy and rising prevalence of rare genetic disorders. In the U.S., chronic diseases such as heart disease, cancer, and diabetes cause most deaths and disabilities, generating about USD 4.9 trillion in annual healthcare costs, as reported by U.S. National health expenditure. Moreover, adoption of advanced viral and non-viral vector technologies is supporting widespread use of specialized gene therapy media.
Europe Gene Therapy Media Market Insights
Europe holds the substantial share in the gene therapy media market driven by increasing clinical trials in gene therapy and expansion of contract development and manufacturing organizations. For instance, in September 2025, Bayer’s AskBio started a Phase 2 trial of AB-1005, a gene therapy using AAV2 vectors to support neuron survival in Parkinson’s patients. Moreover, government funding for rare disease research is supporting market growth. In addition, rising awareness among healthcare providers enhances adoption of advanced media solutions.
Asia Pacific Gene Therapy Media Market Insights
Asia Pacific is the fastest growing market driven by expansion of gene therapy manufacturing facilities in China and India. Moreover, rising prevalence of chronic and genetic diseases is increasing demand for targeted therapies. In India, non-communicable diseases cause over half of deaths and the National Health Policy aims to cut premature deaths by one-third by 2030. In addition, government initiatives promoting biotech research are enhancing market opportunities.
China Gene Therapy Media Market Insights
China is expanding rapidly due to rapid development of cell and gene therapy manufacturing plants. Additionally, higher clinical trial activity and usage of advanced culture media solutions are driving robust growth across the country.
Key Players & Competitive Analysis Report
The gene therapy media market is moderately competitive, and firms are working on serum-free, specialty, and custom media to sustain viral and non-viral vector production. Additionally, partnerships with biotech companies, CDMOs, and research institutes aid scalability, adoption, and international market presence.
Key players in the market for gene therapy media are FUJIFILM Biosciences, Lonza Group AG, IQVIA Inc., Novartis AG, Nucleus Biologics, Sartorius AG, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Amsbio, Cencora, Inc., ElevateBio, Bayer AG, and AstraZeneca.
Key Players
- Agilent Technologies, Inc.
- Amsbio
- AstraZeneca
- Bayer AG
- Cencora, Inc.
- Danaher Corporation
- ElevateBio
- FUJIFILM Biosciences
- IQVIA Inc.
- Lonza Group AG
- Novartis AG
- Nucleus Biologics
- Sartorius AG
- Thermo Fisher Scientific Inc.
Industry Development
- October 2025: Lonza added its TheraPEAK gene therapy media with AmpliCell Cytokines and 293-GT Medium to support AAV vector production and immune cell expansion.
- August 2024: Nucleus Biologics launched QuickStart Media, a gene therapy media designed for T cells, HEK cells, MSCs, and NK cells. It accelerates gene therapy development with flexible, pre-optimized formulations.
Gene Therapy Media Market Segmentation
By Product (Revenue, USD Million, 2020–2034)
- Specialty Media
- Serum-free Media
- Classical Media
- Other Products
By Vector Type (Revenue, USD Million, 2020–2034)
- AAV Production
- LV Production
- Other Vectors
By End User (Revenue, USD Million, 2020–2034)
- Pharmaceutical and Biotechnology Companies
- Contract Development & Manufacturing Organizations (CDMOs) & CROs
- Research and Academic Institutes
By Region (Revenue, USD Million, 2020–2034)
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherland
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
- Latin America
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of South Africa
Gene Therapy Media Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 408.06 Million |
|
Market Size in 2025 |
USD 477.04 Million |
|
Revenue Forecast by 2034 |
USD 2,001.61 Million |
|
CAGR |
17.27% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2025-2034 |
|
Forecast Period |
2025-2034 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions and segmentation. |
FAQ's
The global market size was valued at USD 408.06 million in 2024 and is projected to grow to USD 2,001.61 million by 2034.
The global market is projected to register a CAGR of 17.27% during the forecast period.
North America dominated the gene therapy media market in 2024 due to high adoption of advanced gene therapy platforms and strong biotechnology infrastructure.
A few of the key players in the market are FUJIFILM Biosciences, Lonza Group AG, IQVIA Inc., Novartis AG, Nucleus Biologics, Sartorius AG, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Amsbio, Cencora, Inc., ElevateBio, Bayer AG, and AstraZeneca.
The biological segment dominated in 2024, driven by extensive use of viral vectors in clinical gene therapy applications and continued investment in viral-based delivery research.
The oncology segment is projected to grow fastest, supported by increasing clinical trials for cancer gene therapies and rising demand for targeted treatment solutions.
© 2025 Polaris Market Research and Consulting. All rights reserved
